Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department

Despite the therapy advances, largely due to the study of molecular biology, multiple myeloma remains an incurable disease, and refractory course or relapses significantly worsen the prognosis. In this regard, the development of effective therapeutic agents with fundamentally new mechanisms of action that provide increased survival is currently an urgent task. One potential immunotherapeutic target is signaling lymphocyte activation molecules (SLAMs), and the anti-SLAMF7 monoclonal antibody elotuzumab is used in combination with either lenalidomide and dexamethasone (Elo-Rd regimen) after 1 prior line of therapy, or with pomalidomide and dexamethasone (Elo-Pd regimen) after 2 or more lines of therapy. The results of studies demonstrated a survival benefit in all subgroups of patients with refractory or relapsed multiple myeloma when using elotuzumab. A manageable safety profile and a low frequency of grade III–IV induced myelosuppression were noted, which allows the use of elotuzumab in combination with lenalidomide or pomalidomide and dexamethasone in elderly and debilitated patients. We present our own experience of using elotuzumab in the treatment of patients with refractory/recurrent multiple myeloma. A clinical case of a patient in whom treatment with elotuzumab was initiated at an early stage (after 1 line of previous therapy) is presented; the effectiveness and safety of using the monoclonal antibody are assessed. A significant improvement in the patient’s clinical condition and positive dynamics according to laboratory data were noted already during the 1st cycle of Elo-Rd regimen with a further progressive deepening of the antitumor response along with satisfactory tolerability and the absence of significant adverse events.

1. Kumar S.K., Dimopoulos M.A., Kastritis E. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2017;31(11):2443–8. DOI: 10.1038/leu.2017.138

2. Varga C., Maglio M., Ghobrial I.M., Richardson P.G. Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2018;181(4):447–59. DOI: 10.1111/bjh.15121

3. Taniwaki M., Yoshida M., Matsumoto Y. et al. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling. Mediterr J Hematol Infect Dis 2018;10(1):e2018014. DOI: 10.4084/MJHID.2018.014

4. Hsi E.D., Steinle R., Balasa B. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14(9):2775–84. DOI: 10.1158/1078-0432.CCR-07-4246

5. Ritchie D., Colonna M. Mechanisms of action and clinical development of elotuzumab. Clin Transl Sci 2018;11(3):261–6. DOI: 10.1111/cts.12532

6. Chu E., Wu J., Kang S.S. et al. SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments. Curr Oncol 2023;30(9):7891–903. DOI: 10/3390/curroncol30090573

7. Pazina T., Jamesa A.M., MacFarlane A.W. 4th et al. The antiSLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology 2017;6(9):e1339853. DOI: 10.1080/2162402X.2017.1339853

8. Zonder J.A., Mohrbacher A.F., Singhal S. et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120(3): 552–9. DOI: 10.1182/blood-2011-06-360552

9. Balasa B., Yun R., Belmar N. et al. Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len). J Clin Oncol 2012;30(15_suppl):8087. DOI: 10.1200/jco.2012.30.15_suppl.8087

10. Lonial S., Dimopoulos M., Palumbo A. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373(7):621–31. DOI: 10.1056/NEJMoa1505654

11. Dimopoulos M.A., Lonial S., White D. et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 2020;10(9):91. DOI: 10.1038/s41408-020-00357-4

12. Lopez-Girona A., Mendy D., Ito T. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326–35. DOI: 10.1038/leu.2012.119

13. Dimopoulos M.A., Dytfeld D., Grosicki S. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379(19):1811–22. DOI: 10.1056/NEJMoa1805762

14. Dimopoulos M.A., Dytfeld D., Grosicki S. et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2023;41(3):568–78. DOI: 10.1200/JCO.21.02815

15. Kumar S., Paiva B., Anderson K.C. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328–46. DOI: 10.1016/S1470-2045(16)30206-6